Liver Cancer
Filter News
Found 52 articles
-
The company’s immunotherapy, in combination with chemotherapy Avastin, showed favorable progression-free survival in a late-stage hepatocellular carcinoma study.
-
In a Phase Ib/II study, Tempest Therapeutics’ investigational PPAR⍺ antagonist—combined with Roche’s Avastin and Tecentriq—showed strong signs of survival benefits in liver cancer patients.
-
Following a nearly decade-long effort, Delcath Systems finally won the FDA’s greenlight for its Hepzato Kit for the liver-directed treatment of adult patients with metastatic uveal melanoma.
-
The settlement agreement between the companies follows three patent-infringement lawsuits filed by Bristol-Myers Squibb over the blockbuster cancer immunotherapies.
-
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
7/17/2023
Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4th 2023.
-
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases
4/20/2023
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD ™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases.
-
RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer
3/21/2023
RayzeBio, Inc. today announced the nomination of a first-in-class novel peptide drug candidate against GPC3. As GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, it has a compelling profile for targeted cancer therapy.
-
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
1/24/2023
Galectin Therapeutics Inc. announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics, a prominent peer-reviewed gastroenterology journal.
-
Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform
12/5/2022
Zhongchao Inc. today announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer.
-
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody, Tecentriq, for metastatic bladder cancer.
-
Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology
8/5/2022
Delcath Systems, Inc. announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusion procedure (PHP) with CHEMOSAT® at three European centers, one in the Netherlands and two in Germany, between February 2014 and December 2019.
-
CEVEC's License Partner RZNOMICS Inc. Receives Approval to Initiate Clinical Development of CAP(R) Ad Technology-Produced Gene Therapy Vector in Liver Cancer Patients
7/13/2022
South Korean Ministry of Food and Drug Safety granted IND approval for a clinical phase 1/2a trial to evaluate safety and efficacy of RZNOMICS lead gene therapy RZ001 for the treatment of primary liver cancer.
-
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test
7/5/2022
Helio Genomics, and its commercial partner, Fulgent Genetics announced that the American Medical Association has issued a new Category I Current Procedural Terminology Proprietary Laboratory Analyses code for HelioLiver™, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022.
-
Final analysis of the Himalaya trial demonstrated safety as well as a statistically relevant 22% improvement of overall survival (OS) without exposing the patient to an increase in liver toxicity.
-
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
4/25/2022
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi.
-
Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer
3/7/2022
Helio Health today announced that Hepatology Communications published positive results from the ENCORE study validating HelioLiver's strong clinical performance in detecting the presence of early hepatocellular carcinoma.
-
Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres® Y-90 resin microspheres in China from the National Medical Products Administration
2/9/2022
Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced with its shareholder, Grand Pharmaceutical Group Limited, that SIR-Spheres® Y-90 resin microspheres have been approved by the National Medical Products Administration for the treatment of patients with colorectal cancer liver metastases.
-
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
1/26/2022
Hepion Pharmaceuticals, Inc. today announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody, an immune checkpoint inhibitor (“ICI”).
-
First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer
1/25/2022
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has dosed the first patient in a global Phase 2 clinical trial of MTL-CEBPA in combination with second line standard of care sorafenib ) in advanced hepatocellular carcinoma.
-
AstraZeneca has been struggling to find an effective use for its anti-CTLA-4 antibody tremelimumab. It may have finally found it.